OVERVIEW
Biochemical changes associated with the pathophysiology of Alzheimer disease (AD) are being evaluated to aid in the diagnosis of AD. Some of the most commonly studied biomarkers are amyloid-β peptide 1-42 and total or phosphorylated tau protein in cerebrospinal fluid (CSF). This policy documents whether testing cerebrospinal fluid and urinary biomarkers improves outcomes in individuals with mild cognitive impairment or Alzheimer disease.

MEDICAL CRITERIA
Not applicable

PRIOR AUTHORIZATION
Not applicable

POLICY STATEMENT
Medicare Advantage Plans
Measurement of cerebrospinal fluid biomarkers of Alzheimer disease, including but not limited to tau protein, amyloid-β peptides, or neural thread proteins, is considered not covered as whether earlier diagnosis leads to improved health outcomes through delay of AD onset or improved quality of life is unknown. The evidence is insufficient to determine the effects of the technology on health outcomes.

Measurement of urinary biomarkers of Alzheimer disease is considered not covered, including but not limited to neural thread proteins as whether earlier diagnosis leads to improved health outcomes through delay of AD onset or improved quality of life is unknown. The evidence is insufficient to determine the effects of the technology on health outcomes.

Commercial Products
Measurement of cerebrospinal fluid biomarkers of Alzheimer disease, including but not limited to tau protein, amyloid-β peptides, or neural thread proteins, is considered not medically necessary as whether earlier diagnosis leads to improved health outcomes through delay of AD onset or improved quality of life is unknown. The evidence is insufficient to determine the effects of the technology on health outcomes.

Measurement of urinary biomarkers of Alzheimer disease is considered not medically necessary, including but not limited to neural thread proteins as whether earlier diagnosis leads to improved health outcomes through delay of AD onset or improved quality of life is unknown. The evidence is insufficient to determine the effects of the technology on health outcomes.

COVERAGE
Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for not medically necessary/not covered services.

BACKGROUND
The diagnosis of Alzheimer disease (AD) is divided into 3 categories: possible, probable, and definite AD. A diagnosis of possible AD is made when the patient meets core clinical criteria for AD but has an atypical course or an etiologically mixed presentation. Probable AD is diagnosed clinically when the patient meets core clinical criteria for dementia and has a typical clinical course for AD. A typical clinical course is defined
as an insidious onset, with the initial and most prominent cognitive deficits being either amnestic or non-amnestic (eg, language, visuospatial, or executive function deficits), and a progressively worsening cognition over time. A diagnosis of definite AD requires postmortem confirmation of AD pathology, including the presence of extracellular β-amyloid plaques and intraneuronal neurofibrillary tangles in the cerebral cortex.2

Mild cognitive impairment (MCI) may be diagnosed when a dementia diagnosis cannot be made yet there is a significant change in cognition.3 MCI is characterized by impairment in 1 or more cognitive domains yet there remains preserved functional independence. In some patients, MCI may be a predementia phase of AD. Patients with MCI or suspected AD may undergo ancillary testing (eg, neuroimaging, laboratory tests, neuropsychological assessment) to rule out vascular, traumatic, and medical causes of cognitive decline and to evaluate genetic factors. Because clinical diagnosis can be difficult, particularly early in the course of the disease, there has been considerable interest in developing an accurate laboratory test for AD.

Biomarkers

Several potential biomarkers of Alzheimer disease (AD) are associated with AD pathophysiology (eg, β-amyloid plaques, neurofibrillary tangles). Elevated cerebrospinal fluid (CSF) levels of specific proteins have been found in patients with AD. These include tau protein, phosphorylated at AD-specific epitopes such as phosphorylated threonine 181 or total tau protein, or an amyloid-β peptide such as 1-42 (Aβ42). Other potential CSF and serum peptide markers have been explored. Tau protein is a microtubule-associated molecule found in neurofibrillary tangles that are typical of AD. Tau protein is thought to be related to degenerating and dying neurons and high levels of tau protein in the CSF have been associated with AD. Aβ42 is a subtype of amyloid-β peptide produced from the metabolism of the amyloid precursor protein. Aβ42 is the key peptide deposited in amyloid plaques characteristic of AD. Low levels of Aβ42 in the CSF have been associated with AD, perhaps because Aβ42 is deposited in amyloid plaques instead of remaining in the fluid. Investigators have suggested the tau/Aβ42 ratio may be a more accurate diagnostic marker than either alone.4 A variety of kits are commercially available to measure Aβ42 and tau proteins. Between-laboratory variability in CSF biomarker measurement is large.5,6 Neural thread protein is associated with neurofibrillary tangles of AD. Both CSF and urine levels of this protein have been investigated as a potential marker of AD. Urine and CSF tests for neural thread protein may be referred to as the AD7C test.

For individuals who have AD or mild cognitive impairment (MCI) who receive cerebrospinal fluid (CSF) biomarker testing for AD, the evidence includes systematic reviews and prospective and retrospective studies. These studies assess using CSF biomarkers for diagnosis of AD or for the prognosis of progression of MCI to AD. Relevant outcomes include diagnosis accuracy, correct treatment, avoiding unnecessary subsequent testing, harms of invasive testing, and quality of life (QOL). Most clinical validity studies have been derived from select patient samples and defined optimal test cutoffs without validation; thus, the generalizability of results is uncertain. For predicting conversion from MCI to AD, limited evidence has suggested that testing may define increased risk. Whether an earlier diagnosis leads to improved health outcomes through a delay of AD onset due to medical therapy or other interventions or improved QOL is unknown. The evidence is insufficient to determine that the technology results in an improvement in the net health outcomes.

For individuals who have AD or MCI who receive urinary biomarker testing for AD, the evidence includes a systematic review and prospective and retrospective studies. Relevant outcomes include diagnosis accuracy, correct treatment, avoiding unnecessary subsequent testing, harms of invasive testing, and QOL. Clinical validity studies have included normal healthy controls and defined optimal test cutoffs without validation; thus, clinical validity is uncertain. Whether an earlier diagnosis leads to improved health outcomes through a delay of AD onset or improved QOL is unknown. The evidence is insufficient to determine that the technology results in an improvement in the net health outcomes.
Regulatory Status

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). AlzheimAlert™ and AdMark® CSF analysis are available under the auspices of CLIA. Laboratories that offer laboratory-developed tests must be licensed by CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

CODING

BlueCHiP for Medicare and Commercial

The following codes (effective 10/1/2020) are not covered for Medicare Advantage plans and not medically necessary for Commercial Products.

0206U Neurology (Alzheimer disease); cell aggregation using morphometric imaging and protein kinase C-epsilon (PKCe) concentration in response to amylospheroid treatment by ELISA, cultured skin fibroblasts, each reported as positive or negative for Alzheimer disease (eff 10/1/2020) (PLA code for the DiscernTM test from NeuroDiagnostics)

0207U Neurology (Alzheimer disease); quantitative imaging of phosphorylated ERK1 and ERK2 in response to bradykinin treatment by in situ immunofluorescence, using cultured skin fibroblasts, reported as a probability index for Alzheimer disease (List separately in addition to code for primary procedure) (eff 10/1/2020) (PLA code for the DiscernTM test from NeuroDiagnostics)

CPT code 83520 (Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative; not otherwise specified) may be used to report testing for tau protein and amyloid-β peptides.

For claims filed with date of service prior to 10/1/2020

There are no specific codes for these tests. Claims should be filed with code 81099 when performed in urine and the unlisted immunology code 86849 when performed in CSF.

RELATED POLICIES

None

PUBLISHED

Provider Update, April 2021
Provider Update, January 2020
Provider Update, November/December 2018
Provider Update, June 2017

REFERENCES:


This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member’s subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.